Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
6
×
boston blog main
boston top stories
life sciences
national blog main
clinical trials
national top stories
san francisco blog main
dyne therapeutics
myotonic dystrophy type 1
new york blog main
rare disease drugs
rare diseases
san diego blog main
third rock ventures
abbvie
allergan
ally bridge group
alzheimer's disease
antisense oligonucleotide
astellas pharma
atlas venture
audentes therapeutics
avapritinib
avidity biosciences
benzodiazepines
big data analytics
biogen
biotech ipos
blackrock
blackstone group
blackstone life sciences
bluebird bio
blueprint medicines
cancer
cancer drugs
capmatinib
casdin capital
columbia university
What
genetic
6
×
medicines
drug
ipo
biotech
company
diseases
dyne
experimental
million
muscle
new
raised
rare
research
therapeutics
abbvie
address
ago
aims
alliance
analysis
approval
approves
backed
bio
biotechs
blueprint
bring
brings
cancer
carries
cause
ceo
certain
considering
data
designed
develop
developing
Language
unset
Current search:
boston
×
genetic
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
3 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
